- Home
- BPOPM vs VCEL Comparison
BPOPM vs VCEL Comparison
Compare BPOPM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BPOPM
Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Current Price
Company Overview
Basic Information| Metric | BPOPM | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.4B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BPOPM | VCEL |
|---|---|---|
| Price | $25.09 | $39.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 4.1K | ★ 439.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.69 | ★ 60.00 |
| EPS | ★ 8.13 | N/A |
| Revenue | ★ $756,100,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $3.09 | ★ N/A |
| Revenue Growth | 16.00 | ★ 16.45 |
| 52 Week Low | $24.75 | $28.95 |
| 52 Week High | $25.65 | $49.32 |
Technical Indicators
Market Signals| Indicator | BPOPM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 44.28 |
| Support Level | $25.03 | $35.32 |
| Resistance Level | $25.36 | $41.12 |
| Average True Range (ATR) | 0.11 | 1.20 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 12.77 | 65.91 |
Price Performance
Historical ComparisonAbout BPOPM Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Popular Capital Trust II is a statutory trust. It is engaged in issuing capital securities.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.